The Epilepsy Study Consortium is a collaborative group of scientific investigators from leading academic medical research centers focused on reducing the time it takes to bring effective therapies to patients with epilepsy. They work across various fields to enhance clinical trial methodologies, foster partnerships with industry and regulatory bodies, and streamline the research process to improve treatment outcomes.
2006
20-4950952
$1.784 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
An introduction to the Epilepsy Study Consortium and its members.
A biennial symposium focused on advancing epilepsy therapies and diagnostics.
The importance of collaborative research in advancing new epilepsy therapies.
Clinical Trials Conducted
Assisted with the design and conduct of more than 100 clinical trials since 2007.
New Therapies Approved
Successfully brought 8 new anti-epileptic drugs and devices to market.
May 28-30, 2025
A symposium discussing new epilepsy therapies and diagnostics, aimed at expediting their development.
Learn MoreOverall Score
62
54
/100
Program Expense Ratio
97.65%
20
/20
Program Revenue Growth
105.97%
20
/20
Leverage Ratio
0
2
/20
Working Capital Ratio
0.9301
10
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 621.7K | 29.21% |
Program Services | 1.507M | 70.79% |
Investment Income | 33 | 0.00% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 0 | 0.00% |
Total Revenue | 2.128M | 100.00% |
Health Associations
Epilepsy CareHealth Associations
Epilepsy CareHealth Associations
Epilepsy CareHealth Associations
Epilepsy CareHealth Associations
Epilepsy Care